Annual Drug Patent Expirations for INVEGA+SUSTENNA Invega Sustenna is a drug marketed by Janssen Pharms and is included in one NDA. It is available from one supplier. There are three…
The post New patent expiration for Janssen Pharms drug INVEGA …
New patent expiration for Janssen Pharms drug INVEGA SUSTENNA Read Post »
Annual Drug Patent Expirations for ORBACTIV Orbactiv is a drug marketed by The Medicines Co and is included in one NDA. It is available from one supplier. There are five…
The post New patent expiration for The Medicines drug ORBACTIV appeared fir…
New patent expiration for The Medicines drug ORBACTIV Read Post »
We live in a digital world. The way we interact has undergone a tremendous change in the last decade and this change is gradually reshaping our society itself. It’s difficult…
The post How can pharmaceutical companies play a key role in the digit…
Blockchain based technologies will reach millions of lives Blockchain is making its entry into healthcare and medical fields, and is being prepared for the potential ways in which an ingenious…
The post Blockchain Applications in the Pharmaceutic…
Blockchain Applications in the Pharmaceutical Industry Read Post »
ALVESCO (ciclesonide) Astrazeneca pharmsPatent: 5,482,934Expiration: Oct 24, 2017 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact [email protected] or visit www.DrugP…
Drug Patent Expirations for the Week of October 22, 2017 Read Post »
This is part six of a six-part series on drug lifecycle management: Four Strategic ChoicesPrevention Innovation Extraction Adaptation Summary and Conclusion This article is adapted from Song CH, Han J-W. Patent cliff and strategic switch:…
The post Str…
Strategies for Branded Drug Lifecycle Management: Part 6 – Summary and Conclusion Read Post »
This is part five of a six-part series on drug lifecycle management: Four Strategic ChoicesPrevention Innovation Extraction Adaptation Summary and Conclusion This article is adapted from Song CH, Han J-W. Patent cliff and strategic switch:…
The post St…
Strategies for Branded Drug Lifecycle Management: Part 5 – Adaptation Read Post »
This is part four of a six-part series on drug lifecycle management: Four Strategic ChoicesPrevention Innovation Extraction Adaptation Summary and Conclusion This article is adapted from Song CH, Han J-W. Patent cliff and strategic switch:…
The post St…
Strategies for Branded Drug Lifecycle Management: Part 4 – Extraction Read Post »
This is part three of a six-part series on drug lifecycle management: Four Strategic ChoicesPrevention Innovation Extraction Adaptation Summary and Conclusion This article is adapted from Song CH, Han J-W. Patent cliff and strategic switch:…
The post S…
Strategies for Branded Drug Lifecycle Management: Part 3 – Innovation Read Post »
This is part two of a six-part series on drug lifecycle management: Four Strategic ChoicesPrevention Innovation Extraction Adaptation Summary and Conclusion This article is adapted from Song CH, Han J-W. Patent cliff and strategic switch:…
The post Str…
Strategies for Branded Drug Lifecycle Management: Part 2 – Prevention Read Post »
Get new actionable insights and updates from BiotechBlog
